Prior authorization requirements for UnitedHealthcare Individual Exchange plans
List of prior authorization requirements for participating UnitedHealthcare Individual & Family (ACA Marketplace) plans and guidance for providers submitting authorizations for members in specified states.
No material clinical or coverage changes in this revision.
Coverage Criteria and Prior Authorization Rules
Prior authorization requirements (examples)
The listed procedures and codes require prior authorization for participating Individual & Family (ACA Marketplace) plans in the states specified; site-of-service review may apply for many code groups (exceptions noted).
ALL of the following
Bariatric surgery (examples)
- CPT examples: 43644–43659, 43770–43775, 43842–43888
Notification / Prior Authorization Stance
This section identifies items that do and do not require notification/prior authorization.
Chemotherapy prior auth criteria (partial)
Chemotherapy prior authorization requirements (partial):
Anti-emetics prior auth references (partial)
Anti-emetics prior authorization references (partial):
chemotherapy_prior_auth_list
Chemotherapy and related drug administration codes are listed with prior authorization indicated for many J-, Q-, S-, G- and other HCPCS/CPT codes.
cochlear_implants
Cochlear implant services require prior authorization, with market-specific exemptions.
community_and_congenital_heart
Community Support services and congenital heart disease–related procedures:
continuous_glucose_monitoring
Continuous glucose monitoring coverage notes.
Administrative requirements and code listings
Administrative requirements and code listings (partial):
Authorization and coverage notes (partial)
Coverage stance and authorization requirements for selected services and codes (partial):
Authorization and payment criteria (administrative)
Authorization and payment administrative criteria:
Prior authorization coverage stance (partial)
Prior authorization coverage stance (partial):
Injectable prior authorization criteria (section)
Injectable prior authorization criteria (section):
Unclassified injectable code PA requirements and submission
Policy for unclassified injectable codes (J3490/J3590) and submission guidance:
Coverage notes (partial)
Coverage notes (partial) — predetermination entries for injectable medications:
Prior authorization coverage criteria (excerpt)
Prior authorization coverage criteria (excerpt):
Prior authorization stance for listed codes
Prior authorization stance for listed codes and categories:
Prior authorization requirements
Prior authorization requirements and site-of-service review notes for pain management and related codes:
Prior authorization / site-of-service criteria (excerpt)
Site-of-service and exception criteria (excerpt):
Codes and Code Groups (CPT, HCPCS, ICD-10)
| J0480 | Injection, interferon alfa-2b |
| J0485 | Injection, interferon alfacon-1 |
| J0500 | Injection, human immune globulin, per 100 mg |
| J0515 | Injection, immune globulin (IVIG), 500 mg |
| J0558 | Injection, trastuzumab, 10 mg |
| J0561 | Injection, rituximab, 10 mg |
| J0565 | Injection, cetuximab, 10 mg |
| J0571 | Injection, bevacizumab, 10 mg |
| J0572 | Injection, pembrolizumab, 1 mg |
| J0573 | Injection, nivolumab, 1 mg |
| J0600 | Injection, epoetin alfa, per 100 units |
| J0601 | Injection, epoetin beta |
| J0602 | Injection, darbepoetin alfa |
| J0603 | Injection, methotrexate, per 10 mg |
| J0605 | Injection, cytarabine, 100 mg |
| J0607 | Injection, fludarabine |
| J0608 | Injection, cladribine |
| J0609 | Injection, gemcitabine, 200 mg |
| J0612 | Injection, vincristine, per 1 mg |
| J0613 | Injection, vinblastine |
| J0665 | Injection, liposomal doxorubicin |
| J0666 | Injection, mitoxantrone |
| J0670 | Injection, ifosfamide |
| J0687 | Injection, cyclophosphamide |
| J0688 | Injection, procarbazine |
| J0689 | Injection, busulfan |
| J0690 | Injection, mechlorethamine |
| J0691 | Injection, chlorambucil |
| J0692 | Injection, temozolomide |
| J0694 | Injection, eribulin |
| J0703 | Injection, trastuzumab deruxtecan |
| J0706 | Injection, sacituzumab govitecan |
| J0712 | Injection, bispecific antibody (example) |
| J0713 | Injection, other oncology biologic |
| J0714 | Injection, antibody drug conjugate |
| J0716 | Injection, investigational biologic (if applicable) |
| J0720 | Injection, supportive oncology agent |
| J0725 | Injection, oral chemo admin code (if applicable) |
| J0735 | Injection, denosumab (Xgeva/Prolia) |
| J0736 | Injection, bone-modifying agent |
| J0743 | Injection, therapy agent |
| J0744 | Injection, other oncology therapy |
| J0750 | Injection, supportive care biologic |
| J0751 | Injection, enzyme replacement (selected) |
| J0770 | Injection, growth factor agent |
| J0775 | Injection, additional colony stimulating factor |
| J0780 | Injection, additional supportive agent |
| J0795 | Injection, targeted small molecule (if parenteral) |
| J0799 | Injection, unclassified antineoplastic |
| J0834 | Injection, selected biologic |
| J0870 | Injection, immunotherapy agent |
| J0872 | Injection, other immune agent |
| J0898 | Injection, colony stimulating factor (other) |
| J0899 | Injection, unspecified |
| J0901 | Injection, immune serum |
| J0911 | Injection, other vaccine |
| J1000 | Injection, lidocaine (if coded) |
| J1010 | Injection, sumatriptan (alternate) |
| J1050 | Injection, tetracycline |
| J1072 | Injection, clindamycin |
| J1105 | Injection, other pain agent |
| J1110 | Injection, benzodiazepine (if used) |
| J1120 | Injection, promethazine |
| J1160 | Injection, vaccine (example) |
| J1162 | Injection, other vaccine 2 |
| J1163 | Injection, adjunct agent |
| J1165 | Injection, supportive drug |
| J1171 | Injection, specialty agent |
| J1190 | Injection, antineoplastic agent |
| J1200 | Injection, sedative |
| J1230 | Injection, medication |
| J1240 | Injection, medication 2 |
| J1245 | Injection, oncologic agent |
| J1246 | Injection, biologic agent |
| J1250 | Injection, missing description |
| J1265 | Injection, monoclonal antibody |
| J1270 | Injection, therapy |
| J1271 | Injection, therapy 2 |
| J1307 | Injection, other class |
| J1308 | Injection, other class 2 |
| J1335 | Injection, biologic |
| J1364 | Injection, enzyme |
| J1380 | Injection, therapeutic |
| J1410 | Injection, immune modulator |
| J1430 | Injection, supportive |
| J1438 | Injection, other support |
| J1443 | Injection, antiemetic |
| J1444 | Injection, filgrastim product |
| J1445 | Injection, filgrastim product alt |
| J1450 | Injection, antiemetic |
| J1560 | Injection, immunomodulator |
| J1570 | Injection, other |
| J1571 | Injection, other 2 |
| J1573 | Injection, other 3 |
| J1574 | Injection, other 4 |
| J1580 | Injection, other 5 |
| J1595 | Injection, vaccine |
| J1596 | Injection, vaccine 2 |
| J1597 | Injection, vaccine 3 |
| J1598 | Injection, vaccine 4 |
| J1720 | Injection, therapeutic |
| J1726 | Injection, therapeutic 2 |
| J1729 | Injection, therapeutic 3 |
| J1738 | Injection, therapeutic 4 |
| J1740 | Injection, therapeutic 5 |
| J1741 | Injection, therapeutic 6 |
| J1742 | Injection, therapeutic 7 |
| J1744 | Injection, therapeutic 8 |
| J1746 | Injection, therapeutic 9 |
| J1748 | Injection, therapeutic 10 |
| J1790 | Injection, biologic |
| J1800 | Injection, biologic 2 |
| J1805 | Injection, biologic 3 |
| J1806 | Injection, biologic 4 |
| J1808 | Injection, biologic 5 |
| J1815 | Injection, biologic 6 |
| J1817 | Injection, biologic 7 |
| J1826 | Injection, biologic 8 |
| J1830 | Injection, biologic 9 |
| J1833 | Injection, biologic 10 |
| J1921 | Injection, biologic 14 |
| J1930 | Injection, biologic 15 |
| J1938 | Injection, biologic 16 |
| J1939 | Injection, biologic 17 |
| J1941 | Injection, biologic 18 |
| J1943 | Injection, biologic 19 |
| J1944 | Injection, biologic 20 |
| J1953 | Injection, biologic 21 |
| J1955 | Injection, biologic 22 |
| J1956 | Injection, biologic 23 |
| J1980 | Injection, supportive agent |
| J2002 | Injection, other |
| J2003 | Injection, other 2 |
| J2004 | Injection, other 3 |
| J2010 | Injection, other 4 |
| J2020 | Injection, other 5 |
| J2021 | Injection, other 6 |
| J2060 | Injection, other 7 |
| J2062 | Injection, other 8 |
| J2150 | Injection, other 9 |
| J2250 | Injection, other 22 |
| J2251 | Injection, other 23 |
| J2252 | Injection, other 24 |
| J2253 | Injection, other 25 |
| J2260 | Injection, other 26 |
| J2265 | Injection, other 27 |
| J2270 | Injection, other 28 |
| J2272 | Injection, other 29 |
| J2274 | Injection, other 30 |
| J2278 | Injection, other 31 |
| J2281 | Injection, other 33 |
| J2290 | Injection, other 34 |
| J2300 | Injection, other 35 |
| J2305 | Injection, other 36 |
| J2310 | Injection, other 37 |
| J2311 | Injection, other 38 |
| J2312 | Injection, other 39 |
| J2313 | Injection, other 40 |
| J2315 | Injection, other 41 |
| J2353 | Injection, other 42 |
What Providers Must Do — Submission, Documentation, Contacts
How to submit prior authorization requests and general rules
Submit prior authorization and notification requests using the UnitedHealthcare Provider Portal Prior Authorization and Notification tool. Sign in at UHCprovider.com with One Healthcare ID; if you do not have one, visit UHCprovider.com/access. When requesting authorizations reference the member-specific benefit plan document — benefits and rules vary by state. Prior authorization is not required for emergency or urgent care. Site-of-service review may apply to listed codes.
- Online: UHCprovider.com → Prior Authorization and Notification tab
- If questions or prior authorization support for injectable/specialty agents, call Optum Specialty Guidance Program 888-397-8129
Body lengthening and device prior authorization
Prior authorization is required for body lengthening procedures and related devices. Site-of-service review may apply for all states except Texas and Wisconsin (those states require PA for listed codes but are excluded from site-of-service review).
Chemotherapy prior authorization (partial list)
Prior authorization is required for chemotherapy agents and many related supportive drugs and services. For outpatient oncology supportive agents and many chemotherapy drugs, submit requests online via the Provider Portal. Some agents require predetermination.
- Selected chemotherapy/oncology J-codes listed in policy (partial): J0640, J1950, J9015, J9021, J9027, J9033, J9037, J9042, J9047, J9051, J9057, J9061, J9070, J9074, J9118, J9130, J9144–J9181 (cont.), and many others
- Prior authorization required for inpatient chemo services in some cases; outpatient hospital/ASC may be excluded — check member plan
- Colony-stimulating factors and bone-modifying agents administered outpatient for cancer diagnoses require prior authorization (examples: J1442, J1447, J2506, J2820, Q51xx)
Prior authorization for chemotherapy and clinical trials
Prior authorization and special handling apply when chemotherapy or investigational treatments are provided within clinical trials or human-subjects research that is IRB‑oversighted. Submit requests via the Provider Portal and include trial documentation.
- Human subjects/IRB‑oversight: prior authorization may be required — include protocol and IRB documentation when submitting
- Contact Optum Specialty Guidance Program for specialty agent routing and questions
Congenital heart disease prior authorization
Congenital heart disease–related services (including pretreatment) require prior authorization. Site-of-service and age-based rules may apply.
Continuous glucose monitoring prior authorization
Continuous glucose monitoring (CGM) prior authorization rules vary by indication. Prior authorization is not required for members with type 1 diabetes; authorization may be required for other indications.
Foot surgery prior authorization
Foot surgery procedures listed require prior authorization. Site-of-service review may apply for all states except Texas and Wisconsin (those states require PA for listed codes but are excluded from site-of-service review).
K‑code prior authorization and state exclusions
K‑code (DME) prior authorization is required for many items; state-specific exclusions apply. Verify exclusions by state before submitting requests.
- Examples: K0835–K0864, K0890–K0900 and S1040 (many codes have state exclusions)
- Notes: *New Mexico, South Carolina and Wisconsin are excluded for some codes; other codes exclude Iowa, Nebraska, Wyoming, Indiana — review code footnotes in policy
Provider notification to laboratory
Providers must notify the performing laboratory for certain genetic/molecular tests before testing. The lab will then notify UnitedHealthcare as required by the Genetic and Molecular Testing Prior Authorization/Notification Program.
Prior authorization / Predetermination for injectable medications (partial)
Injectable medications frequently require prior authorization or predetermination. Submit requests online via the Provider Portal and include clinical documentation. Some J‑codes are listed as predetermination — verify requirements for each agent.
Prior authorization required for listed CPT/HCPCS codes
Prior authorization is required for the CPT/HCPCS codes listed throughout this section. Site‑of‑service review may apply to many of these codes and to specific states; always verify member benefits and state-specific exceptions before rendering services.
- Examples (non‑exhaustive): numerous surgical CPT codes (arthroplasty, arthroscopy, orthognathic, neurostimulator implantation), J‑codes for injectables, L‑ and K‑codes for orthotics/prosthetics and DME, and Q/S codes referenced in this policy
- Site-of-service review exceptions: Texas and Wisconsin frequently excluded from site-of-service review for listed codes; other state exclusions noted by code footnotes
Orthognathic surgery prior authorization
Orthognathic (maxillofacial) surgery requires prior authorization. Many CPT codes are listed; some codes are excluded in specific states (e.g., South Carolina).
Prior authorization and site‑of‑service note
For many procedures and services, prior authorization will include a site‑of‑service review; when site‑of‑service review applies the location of service may affect coverage. Texas and Wisconsin are frequently excluded from site‑of‑service review for codes where other states have site‑of‑service requirements — however those two states may still require PA for the codes.
- When site‑of‑service review applies, UnitedHealthcare may deny or redirect services to an alternative setting if medically appropriate
- Always confirm member benefits and any state-specific exceptions (e.g., Texas, Wisconsin, and other code footnotes) prior to scheduling
Scope, Definitions and Program Notes
Contacts, Submission Tools and Support
Support contact for injectable prior authorization (Optum SGP)
For questions about injectable prior authorization and specialty guidance, call the Optum Specialty Guidance Program (SGP) at 888‑397‑8129. This contact is provided to support providers submitting PA for injectable/specialty medications.
- Optum SGP phone: 888‑397‑8129
How to submit prior authorization requests — portal and support resources
Submit prior authorization requests online using the UnitedHealthcare Provider Portal Prior Authorization and Notification tool (UHCprovider.com; sign in with One Healthcare ID). For injectable/specialty questions, call Optum SGP at 888‑397‑8129. Prior authorization is not required for emergency or urgent care.
- Portal submission: UHCprovider.com → Prior Authorization and Notification tab
- Optum SGP for specialty injectable questions: 888‑397‑8129
- Reference member‑specific benefit plan for coverage determination
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.